HomeBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Nakaraang pagsara
$68.38
Sakop ng araw
$66.01 - $67.94
Sakop ng taon
$61.15 - $96.65
Market cap
12.84B USD
Average na Volume
1.39M
P/E ratio
40.53
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 745.74M | 28.28% |
Gastos sa pagpapatakbo | 443.39M | 4.88% |
Net na kita | 106.08M | 162.72% |
Net profit margin | 14.22 | 104.60% |
Kita sa bawat share | 0.91 | 97.83% |
EBITDA | 132.90M | 136.43% |
Aktuwal na % ng binabayarang buwis | 21.10% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 930.44M | -17.36% |
Kabuuang asset | 6.85B | 1.38% |
Kabuuang sagutin | 1.44B | -22.75% |
Kabuuang equity | 5.41B | — |
Natitirang share | 190.58M | — |
Presyo para makapag-book | 2.41 | — |
Return on assets | 4.09% | — |
Return on capital | 4.59% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 106.08M | 162.72% |
Cash mula sa mga operasyon | 221.48M | 63.28% |
Cash mula sa pag-invest | -16.16M | 64.72% |
Cash mula sa financing | -499.12M | -63,240.74% |
Net change in cash | -296.70M | -425.93% |
Malayang cash flow | 165.57M | 86.81% |
Tungkol
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Itinatag
Mar 1997
Headquarters
Website
Mga Empleyado
3,401
